1 BTC
=
- USD
State Street SPDR S&P Biotech ETF
As of May 30, 2026 at 09:05 UTC
Chart
About State Street SPDR S&P Biotech ETF
No description available.
Market Statistics
Trading Metrics
How to Buy XBI
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy XBI
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe Vanguard Health Care ETF (VHT) offers broader healthcare sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.69%), while the SPDR S&P Biotech ETF (XBI) provides targeted biotech exposure with higher volatility but stronger recent 1-year returns (62.20% vs 13.00%). VHT is better suited for income-seeking investors seeking diversified healthcare exposure, while XBI appeals to aggressive investors seeking biotech-specific growth.
Major pharmaceutical companies face a patent cliff with $175 billion in annual drug sales losing exclusivity over the next six years, prompting increased M&A activity. Two biotech ETFs—SPDR S&P Biotech (XBI) and iShares Biotechnology (IBB)—offer investors exposure to capitalize on industry volatility and potential winners from consolidation.
Nextech Invest, a Switzerland-based biotech-focused fund, increased its stake in Relay Therapeutics by 855,097 shares (~$6.1 million). The purchase brings Relay to 3.85% of Nextech's portfolio. Relay's stock has surged 197% over the past year, driven by its computational drug discovery platform and clinical-stage pipeline including lead candidates RLY-4008 and RLY-2608.
NVIDIA's GTC AI Conference (March 16-19) is a critical moment for the stock and broader market. NVDA is precariously positioned near its 200-day moving average after a 15% crash from its $203 post-earnings peak. The stock's performance during CEO Jensen Huang's keynote could determine whether the S&P 500 breaks out to new highs or triggers a bearish correction. Key support levels are at $170-$175, with a breakdown potentially leading to a head-and-shoulders pattern targeting $130-$135.
The FDA has reversed its previous refusal-to-file decision and accepted Moderna's biologics license application for mRNA-1010, an mRNA-based flu vaccine for adults 50 and older, with an August 5 PDUFA goal date. The stock surged 5.77% on the news. Moderna also beat Q4 earnings expectations with a smaller loss and higher-than-expected revenue of $678 million.
